But how many people died? Health outcomes in perspective

Cleveland Clinic Journal of Medicine

Volumn 82, Issue 3, 2015, Pages 146-150

  Prasad, Vinay ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CAUSE OF DEATH; HEALTH; HUMAN; MORTALITY; NEOPLASM; SURVIVAL RATE; TRENDS;

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; GLOBAL HEALTH; HUMANS; NEOPLASMS; SURVIVAL RATE;

EID: 85016649850     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.82a.14058     Document Type: Note

References (38)

1. Cassidy A, Mukamal KJ, Liu L, Franz M, Eliassen AH, Rimm EB. High anthocyanin intake is associated with a reduced risk of myocardial infarction in young and middle-aged women. Circulation 2013; 127:188-196
2. Muraki I, Imamura F, Manson JE, et al. Fruit consumption and risk of type 2 diabetes: results from three prospective longitudinal cohort studies. BMJ 2013; 347:f5001
3. Arem H, Reedy J, Sampson J, et al. The Healthy Eating Index 2005 and risk for pancreatic cancer in the NIH-AARP study. J Natl Cancer Inst 2013; 105 :1298-1305
4. Watanabe I, Kuriyama S, Kakizaki M, et al. Green tea and death from pneumonia in Japan: the Ohsaki cohort study. Am J Clin Nutr 2009; 90 :672-679
5. Prasad V, Jorgenson J, Ioannidis JP, Cifu A. Observational studies often make clinical practice recommendations: an empirical evaluation of authors' attitudes. J Clin Epidemiol 2013; 66:361-366.e4
6. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2197-2223
7. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338:736-746
8. Looker AC. Interaction of science, consumer practices and policy: calcium and bone health as a case study. J Nutr 2003; 133:1987S-1991S
9. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010; 341:c3691
10. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011; 342:d2040
11. Xiao Q, Murphy RA, Houston DK, Harris TB, Chow WH, Park Y. Dietary and supplemental calcium intake and cardiovascular disease mortality: the National Institutes of Health-AARP diet and health study. JAMA Intern Med 2013; 173:639-646
12. The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365:395-409
13. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2013 Jun 4;6:CD001877
14. Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 2002; 94:167-173
15. Fall K, Fang F, Mucci LA, et al. Immediate risk for cardiovascular events and suicide following a prostate cancer diagnosis: prospective cohort study. PLoS Med 2009; 6:e1000197
16. Prasad V. An unmeasured harm of screening. Arch Intern Med 2012; 172 :1442-1443
17. Guirguis-Blake JM, Beil TL, Senger CA, Whitlock EP. Ultrasonography screening for abdominal aortic aneurysms: a sytematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2014; 160:321-329
18. Harris R, Sheridan S, Kinsinger L. Time to rethink screening for abdominal aortic aneurysm? Arch Intern Med 2012; 172:1462-1463
19. Thompson IM Jr, Goodman PJ, Tangen CM, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med 2013; 369 :603-610
20. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:216-224
21. Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in highrisk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 2010; 170:1024-1031
22. Redberg RF, Katz MH. Healthy men should not take statins. JAMA 2012; 307 :1491-1492
23. McEvoy JW, Blumenthal RS, Blaha MJ. Statin therapy for hyperlipidemia. JAMA 2013; 310:1184-1185
24. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007; 356:2131-2142
25. Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172:209-216
26. US Food and Drug Administration. Use of aspirin for primary prevention of heart attack and stroke. www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm390574.htm. Accessed February 5, 2015
27. Ioannidis JP. Mega-trials for blockbusters. JAMA 2013; 309:239-240
28. Dunkler D, Dehghan M, Teo KK, et al; ONTARGET Investigators. Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus. JAMA Intern Med 2013; 173:1682-1692
29. Schoenfeld JD, Ioannidis JP. Is everything we eat associated with cancer? A systematic cookbook review. Am J Clin Nutr 2013; 97:127-134
30. Prasad V, Jena AB. Prespecified falsification end points: can they validate true observational associations? JAMA 2013; 309:241-242
31. Ioannidis JPA. The importance of potential studies that have not existed and registration of observational data sets. JAMA 2012; 308:575-576
32. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004; 64:2634-2638
33. William WN Jr, Papadimitrakopoulou VA. Optimizing biomarkers and endpoints in oral cancer chemoprevention trials. Cancer Prev Res (Phila) 2013; 6:375-378
34. Prasad V. Powering cancer screening for overall mortality. Ecancermedicalscience 2013 Oct 9; 7:ed27
35. US Preventive Services Task Force. Final recommendation statement. Prostate cancer: screening. http://www.uspreventiveservicestaskforce. org/Page/Document/RecommendationStatementFinal/prostate-cancerscreening. Accessed February 5, 2015
36. Prasad V, Cifu A, Ioannidis JP. Reversals of established medical practices: evidence to abandon ship. JAMA 2012; 307:37-38
37. Prasad V, Vandross A, Toomey C, et al. A decade of reversal: an analysis of 146 contradicted medical practices. Mayo Clin Proc 2013; 88:790-798
38. Elshaug AG, Garber AM. How CER could pay for itself-insights from vertebral fracture treatments. N Engl J Med 2011; 364:1390-1393